APhA: FDA in March approved a ketamine cousin called esketamine (Spravato—Janssen), taken as a nasal spray, for patients with intractable depression. Critics claim Janssen provided the agency at best modest evidence it worked and then only in limited trials. It presented no information about the safety of esketamine for long-term use beyond 60 weeks. Three patients who received the drug died by suicide during clinical trials, compared with none in the control group, raising concerns Janssen and FDA dismissed.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now